Future studies including more genes (such as TOP-I [20], PARP [21], and Aprataxin(APTX) [22]) will be carried out to identify and target the most sensitive gastric cancer subpopulation for personalized CPT-11 therapy. This evidence concerns the gene TOP1 and gastric cancer.